ES3028360T3 - Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof - Google Patents

Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof Download PDF

Info

Publication number
ES3028360T3
ES3028360T3 ES18824477T ES18824477T ES3028360T3 ES 3028360 T3 ES3028360 T3 ES 3028360T3 ES 18824477 T ES18824477 T ES 18824477T ES 18824477 T ES18824477 T ES 18824477T ES 3028360 T3 ES3028360 T3 ES 3028360T3
Authority
ES
Spain
Prior art keywords
compound
mmol
added
cancer
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18824477T
Other languages
English (en)
Spanish (es)
Inventor
Yihan Wang
Zhiqiang Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Targetrx Inc
Original Assignee
Shenzhen Targetrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Targetrx Inc filed Critical Shenzhen Targetrx Inc
Application granted granted Critical
Publication of ES3028360T3 publication Critical patent/ES3028360T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES18824477T 2017-06-26 2018-06-25 Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof Active ES3028360T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710493544 2017-06-26
PCT/CN2018/092588 WO2019001383A1 (zh) 2017-06-26 2018-06-25 用于抑制Bcl-2蛋白的N-苯磺酰基苯甲酰胺类化合物及其组合物及应用

Publications (1)

Publication Number Publication Date
ES3028360T3 true ES3028360T3 (en) 2025-06-19

Family

ID=63772870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18824477T Active ES3028360T3 (en) 2017-06-26 2018-06-25 Deuterated n-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof

Country Status (6)

Country Link
US (1) US11718611B2 (enExample)
EP (1) EP3626241B1 (enExample)
JP (2) JP7374496B2 (enExample)
CN (2) CN110759908B (enExample)
ES (1) ES3028360T3 (enExample)
WO (1) WO2019001383A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111747949B (zh) * 2019-03-29 2022-07-01 首药控股(北京)股份有限公司 Bcl-2选择性抑制剂的制备方法
WO2021083135A1 (en) 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
CN116969937B (zh) 2020-04-15 2026-03-24 百济神州(苏州)生物科技有限公司 Bcl-2抑制剂
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
CN115697967B (zh) * 2020-07-10 2024-10-22 江苏恒瑞医药股份有限公司 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
CN114835704B (zh) * 2021-02-01 2023-10-27 苏州亚盛药业有限公司 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
US20240408085A1 (en) * 2021-09-01 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Compound for degradation of bcl-2 family proteins and medical application thereof
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors
CN115286689B (zh) * 2022-09-29 2023-01-06 上海睿跃生物科技有限公司 靶向降解Bcl-2蛋白的化合物及其应用和药物
CN115872963A (zh) * 2022-12-27 2023-03-31 南京哈柏医药科技有限公司 一种维奈托克中间体的合成方法
CN118373787A (zh) * 2024-04-26 2024-07-23 苏州九鹭生物医药有限公司 一种氘代n-酰基磺酰胺类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
ES2546294T7 (es) 2009-05-26 2024-06-06 Abbvie Ireland Unlimited Co Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2012071336A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Salts and crystalline forms of an apoptosis-inducing agent
RU2593231C2 (ru) * 2010-11-23 2016-08-10 ЭббВи Айэленд Анлимитед Компани Способы лечения с использованием селективных ингибиторов bcl-2
CN103987711B (zh) * 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3481397A1 (en) * 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax

Also Published As

Publication number Publication date
US20200216442A1 (en) 2020-07-09
US11718611B2 (en) 2023-08-08
EP3626241A1 (en) 2020-03-25
EP3626241A4 (en) 2020-05-27
CN110759908A (zh) 2020-02-07
CN108658983B (zh) 2019-12-20
JP2022071077A (ja) 2022-05-13
EP3626241B1 (en) 2025-04-23
CN110759908B (zh) 2021-03-12
CN108658983A (zh) 2018-10-16
JP7374496B2 (ja) 2023-11-07
WO2019001383A1 (zh) 2019-01-03
JP2020527166A (ja) 2020-09-03

Similar Documents

Publication Publication Date Title
US11718611B2 (en) Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof
ES2898765T3 (es) Compuestos de quinazolina sustituidos y métodos de uso de los mismos
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
WO2021190467A1 (zh) 含螺环的喹唑啉化合物
ES2773138T3 (es) Derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1H-pirrolo[2,3-c]piridina como inhibidores de NIK para el tratamiento del cáncer
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
JP2021502386A (ja) Ａｓｈ１ｌ分解剤及びそれを用いた治療方法
BR112018003634B1 (pt) Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
US9273005B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
WO2020114388A1 (zh) 取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
CN115368378B (zh) 取代的大环化合物及包含该化合物的组合物及其用途
ES3059451T3 (en) Compound used as ret kinase inhibitor and application thereof
CN104557871A (zh) 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途
WO2019154091A1 (zh) 取代的二氨基嘧啶化合物
PT2937344T (pt) Derivados piridinil e pirazinil-metoxi-arilo úteis como inibidores de tirosina quinase de baço (syk)
CN113906040A (zh) 用于治疗癌症的化合物
ES2784325T3 (es) Formas cristalinas de sales farmacéuticamente aceptables de N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamina y usos de las mismas
ES2976576T3 (es) Formas cristalinas de un inhibidor de la fosfoinositida 3-quinasa (pi3k)
CN104557913B (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN108026046A (zh) 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途
WO2019228330A1 (zh) 取代的苯并[d]咪唑类化合物及其药物组合物
EP3816162B1 (en) Diarylpyrazole compound, composition comprising same, and use thereof
ES2532476T3 (es) Sales de aminas orgánicas de derivados de ácido aminobenzoico, y método para su producción
EP4596553A1 (en) Salt of dioxane quinoline compound, crystal form thereof, preparation methods therefor and uses thereof
HK40114858A (en) Prmt5-mta inhibitor